Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-01-03 5:10 pm Unchanged | 2021-12-29 | 13D | Mersana Therapeutics, Inc. MRSN | Bain Capital Life Sciences Fund II, L.P. | 131,777 4.500% | 0 (Unchanged) | Filing History |
| 2021-11-05 5:16 pm Purchase | 2021-10-26 | 13G | Xilio Therapeutics, Inc. XLO | Bain Capital Life Sciences Fund II, L.P. | 96,334 5.100% | 96,334 (New Position) | Filing History |
| 2021-09-24 5:15 pm Sale | 2021-09-22 | 13D | Atea Pharmaceuticals, Inc. AVIR | Bain Capital Life Sciences Fund II, L.P. | 3,178,532 3.800% | -846,856 (-21.04%) | Filing History |
| 2021-09-03 5:00 pm Sale | 2021-09-01 | 13D | Atea Pharmaceuticals, Inc. AVIR | Bain Capital Life Sciences Fund II, L.P. | 4,025,388 4.900% | -757,714 (-15.84%) | Filing History |
| 2021-08-04 5:11 pm Purchase | 2021-08-02 | 13D | Nuvalent, Inc. NUVL | Bain Capital Life Sciences Fund II, L.P. | 2,400,630 5.600% | 2,400,630 (New Position) | Filing History |